3/12
04:57 pm
fblg
FibroBiologics (FBLG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $7.00 price target on the stock.
Medium
Report
FibroBiologics (FBLG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $7.00 price target on the stock.
3/12
08:30 am
fblg
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
Low
Report
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
3/5
08:30 am
fblg
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Medium
Report
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
3/2
08:30 am
fblg
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
High
Report
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
2/26
08:30 am
fblg
FibroBiologics to Present at the BIO Investment & Growth Summit
Medium
Report
FibroBiologics to Present at the BIO Investment & Growth Summit
2/26
07:17 am
fblg
FibroBiologics (FBLG) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
FibroBiologics (FBLG) had its "buy" rating reaffirmed by HC Wainwright.
2/25
04:45 pm
fblg
FibroBiologics (FBLG) had its price target lowered by D. Boral Capital from $15.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
FibroBiologics (FBLG) had its price target lowered by D. Boral Capital from $15.00 to $7.00. They now have a "buy" rating on the stock.
2/24
04:30 pm
fblg
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
2/23
08:30 am
fblg
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
Medium
Report
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
2/10
08:30 am
fblg
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
Medium
Report
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
2/5
08:30 am
fblg
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
High
Report
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
1/20
08:30 am
fblg
FibroBiologics to Present at the DealFlow Discovery Conference
Medium
Report
FibroBiologics to Present at the DealFlow Discovery Conference
1/7
08:30 am
fblg
FibroBiologics CEO Issues Letter to Shareholders
High
Report
FibroBiologics CEO Issues Letter to Shareholders
1/6
09:55 am
fblg
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/6
08:30 am
fblg
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
High
Report
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
1/5
09:15 am
fblg
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease [Yahoo! Finance]
Low
Report
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease [Yahoo! Finance]
1/5
08:30 am
fblg
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
Low
Report
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
12/31
08:30 am
fblg
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
Medium
Report
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis